A Phase 3 interventional study of Inclacumab in Sickle Cell Disease, Vaso-occlusive Crisis and Vaso-occlusive Pain Episode in Sickle Cell Disease, sponsored by Pfizer. Terminated at 50 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.
Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one is the 7th largest by enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2022, is one of 17 in phase 3, and was the 44th registered.
104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.
Browse Vaso-Occlusive Crises studies →13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18–88
Mohsen Saidinejad · Sites in United States
Ages 5–20
CSL Behring · Sites in United States, Belgium, France and 4 more countries
Ages 18+
CSL Behring · Sites in United States, Turkey, United Kingdom
Ages 12+
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 2 more countries
Ages 12–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 17 · Phase 4 6
First in 2000; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.
Median enrollment 63 across the 56 interventional studies, 82 across the 4 observational. Of the 41 that completed or were terminated, 22 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 60 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
Pfizer has 4 studies filed under Vaso-Occlusive Crises — fewer than ten, so there is no comparison to draw.
3 of the studies in Vaso-Occlusive Crises with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989567Phase 3Asklepion Pharmaceuticals, LLCA Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis | 2027-06 |
| NCT03353584St. Jude Children's Research HospitalEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease | 2026-11 |
| NCT06699849CSL BehringSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis | 2027-10-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 60 studies in Vaso-Occlusive Crises with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.
All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.
104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.
This study's enrollment of 241 is above the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.
Browse Vaso-Occlusive Crises studies →Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
Compared within Vaso-Occlusive Crises, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia, Sickle Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who meet all the following criteria will be eligible for study enrollment:
Female participants of are required to have a negative urine pregnancy test prior to dosing on Day 1.
Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.
Exclusion Criteria:
Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclacumab 30 mg/kg administered intravenously (IV)
Drug: Inclacumab
Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs.
Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of Vaso-occlusive Crises (VOCs)
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years).
Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for \>= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years).
Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Number of Inpatient Hospitalization Days for a VOC
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years).
Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of SCD-related Urgent Care Visits
Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years).
Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure.
Time frame: From first dose of study treatment (Day 1) up to Week 48
Annualized Rate of Complicated VOCs
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years).
Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of Red Blood Cell (RBC) Transfusions
Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years).
Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
| Milestone | Inclacumab |
|---|---|
| Started | 241 |
| Completed | 0 |
| Not completed | 241 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Physician decision | 6 |
| Withdrew: Pregnancy | 7 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Study terminated by sponsor | 179 |
| Withdrew: Withdrawal by subject | 20 |
| Withdrew: Other | 7 |
| Withdrew: Adverse event | 18 |
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs.
| Participants | Inclacumab |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 211 |
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years).
| VOC events per person-year | Inclacumab |
|---|---|
| Annualized Rate of Vaso-occlusive Crises (VOCs) | 1.89 (1.76 to 2.03) |
A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for \>= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years).
| VOC events per person-year | Inclacumab |
|---|---|
| Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication | 1.07 (0.97 to 1.17) |
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years).
| Hospitalization days per person-year | Inclacumab |
|---|---|
| Annualized Number of Inpatient Hospitalization Days for a VOC | 7.07 (6.82 to 7.33) |
Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years).
| Visits per person-year | Inclacumab |
|---|---|
| Annualized Rate of SCD-related Urgent Care Visits | 2.53 (2.38 to 2.69) |
The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure.
| Percentage of Days | Inclacumab |
|---|---|
| Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks | 6.2 ± 8.25 |
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years).
| VOC events per person-year | Inclacumab |
|---|---|
| Annualized Rate of Complicated VOCs | 0.09 (0.06 to 0.12) |
Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years).
| RBC transfusions per person-year | Inclacumab |
|---|---|
| Annualized Rate of Red Blood Cell (RBC) Transfusions | 0.76 (0.68 to 0.85) |
Collected over From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inclacumab | 17/241 (7.1%) | 97/241 (40.2%) | 203/241 (84.2%) |
| Event | Inclacumab |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 35/241 |
| MalariaInfections and infestations | 23/241 |
| Urinary tract infectionInfections and infestations | 8/241 |
| PneumoniaInfections and infestations | 6/241 |
| Bacterial infectionInfections and infestations | 5/241 |
| InfectionInfections and infestations | 4/241 |
| SepsisInfections and infestations | 4/241 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 3/241 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 2/241 |
| GastroenteritisInfections and infestations | 2/241 |
| Event | Inclacumab |
|---|---|
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 68/241 |
| MalariaInfections and infestations | 58/241 |
| Upper respiratory tract infectionInfections and infestations | 42/241 |
| HeadacheNervous system disorders | 42/241 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 26/241 |
| Urinary tract infectionInfections and infestations | 24/241 |
| AnaemiaBlood and lymphatic system disorders | 19/241 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 18/241 |
| TonsillitisInfections and infestations | 17/241 |
| Back painMusculoskeletal and connective tissue disorders | 17/241 |
| Age, Continuous(Years) | Inclacumab |
|---|---|
| Mean | 25.0 ± 7.36 |
| Sex: Female, Male(Participants) | Inclacumab |
|---|---|
| Female | 122 |
| Male | 119 |
| Ethnicity (NIH/OMB)(Participants) | Inclacumab |
|---|---|
| Hispanic or Latino | 37 |
| Not Hispanic or Latino | 200 |
| Unknown or Not Reported | 4 |
| Race/Ethnicity, Customized(Participants) | Inclacumab |
|---|---|
| Race — African | 138 |
| Race — American Indian or Alaska Native | 4 |
| Race — Arab | 3 |
| Race — Black or African American | 43 |
| Race — Middle Eastern | 2 |
| Race — White | 16 |
| Race — Multiracial | 33 |
| Race — Other | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2022 to primary completion in Nov 2025, 43 months.
Results were first posted in Nov 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclacumab